Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazuhiro Yoshimura

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Translational Cancer Research|September 12, 2022
Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancerMitsuhisa Nishimoto, Kazutoshi Fujita, Yutaka Yamamoto, et al.
Frontiers in Oncology|January 7, 2022
Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched AnalysisNaoki Matsumura, Kazutoshi Fujita, Mitsuhisa Nishimoto, et al.
The Prostate|January 31, 2025
Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration-Sensitive Prostate Cancer Patients Receiving Abiraterone AcetateMitsuhisa Nishimoto, Marco A De Velasco, Yutaka Yamamoto, et al.
Cancer Diagnosis & Prognosis|July 5, 2023
Prognosis of Patients Receiving Chemotherapy for Metastatic Upper Tract Urothelial Carcinoma Compared With Metastatic Urinary Bladder CancerShogo Adomi, Kazutoshi Fujita, Hiroyuki Kita, et al.
World Journal of Urology|November 4, 2022
Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patientsTakashi Ueda, Kazutoshi Fujita, Mitsuhisa Nishimoto, et al.
Cancer Diagnosis & Prognosis|July 4, 2024
Gleason Pattern 5 May Be a Prognostic Factor in Radium-223 TreatmentMitsuhisa Nishimoto, Kazutoshi Fujita, Aritoshi Ri, et al.
Current Oncology (Toronto, Ont.)|June 23, 2022
Trop-2 in Upper Tract Urothelial CarcinomaEisuke Tomiyama, Kazutoshi Fujita, Kosuke Nakano, et al.
Scientific Reports|July 2, 2025
Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancersShogo Adomi, Kazuko Sakai, Yurie Kura, et al.
Translational Andrology and Urology|August 25, 2021
Higher neutrophil-to-lymphocyte ratio after the first cycle of the first-line chemotherapy is associated with poor cancer specific survival of upper urinary tract carcinoma patientsMamoru Hashimoto, Kazutoshi Fujita, Takahito Nakayama, et al.
Anti-Cancer Drugs|September 6, 2021
Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinomaMamoru Hashimoto, Takahito Nakayama, Saizo Fujimoto, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Translational Cancer Research|September 12, 2022
Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancerMitsuhisa Nishimoto, Kazutoshi Fujita, Yutaka Yamamoto, et al.
Frontiers in Oncology|January 7, 2022
Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched AnalysisNaoki Matsumura, Kazutoshi Fujita, Mitsuhisa Nishimoto, et al.
The Prostate|January 31, 2025
Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration-Sensitive Prostate Cancer Patients Receiving Abiraterone AcetateMitsuhisa Nishimoto, Marco A De Velasco, Yutaka Yamamoto, et al.
Cancer Diagnosis & Prognosis|July 5, 2023
Prognosis of Patients Receiving Chemotherapy for Metastatic Upper Tract Urothelial Carcinoma Compared With Metastatic Urinary Bladder CancerShogo Adomi, Kazutoshi Fujita, Hiroyuki Kita, et al.
World Journal of Urology|November 4, 2022
Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patientsTakashi Ueda, Kazutoshi Fujita, Mitsuhisa Nishimoto, et al.
Cancer Diagnosis & Prognosis|July 4, 2024
Gleason Pattern 5 May Be a Prognostic Factor in Radium-223 TreatmentMitsuhisa Nishimoto, Kazutoshi Fujita, Aritoshi Ri, et al.
Current Oncology (Toronto, Ont.)|June 23, 2022
Trop-2 in Upper Tract Urothelial CarcinomaEisuke Tomiyama, Kazutoshi Fujita, Kosuke Nakano, et al.
Scientific Reports|July 2, 2025
Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancersShogo Adomi, Kazuko Sakai, Yurie Kura, et al.
Translational Andrology and Urology|August 25, 2021
Higher neutrophil-to-lymphocyte ratio after the first cycle of the first-line chemotherapy is associated with poor cancer specific survival of upper urinary tract carcinoma patientsMamoru Hashimoto, Kazutoshi Fujita, Takahito Nakayama, et al.
Anti-Cancer Drugs|September 6, 2021
Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinomaMamoru Hashimoto, Takahito Nakayama, Saizo Fujimoto, et al.
Pageof 11